Dong Wha Pharmaceuticals and Kyung Hee University Sign Technology Transfer Agreement
August 18, 2014 at 05:47 am
Share
Dong Wha Pharmaceuticals and Kyung Hee University have signed an agreement to transfer technologies used to develop treatments for inflammatory and immune diseases including inflammatory vowel disease. The technology transfer is related to two natural complex extracts developed by Professor Kim Dong-hyun, Pharmacology School of Kyung Hee University, which are effective to treat inflammatory bowel diseases. The treatment using the two natural extracts has been proven its superior efficacy compared to existing compounds in a number of animal model tests.
It is expected to demonstrate similar anti-inflammatory effects on local inflammation versus 5-aminosalicylic acid strain medicines, and further stimulates immune regulation throughout the body after absorption.
DONGWHA PHARM.CO., LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. It also provides medicine raw materials, health food and drinks, as well as cosmetics. The Company distributes its products within domestic market and to overseas markets.